← Insider buys
LXRX

Lexicon Pharmaceuticals, Inc. · Healthcare

Invus Public Equities, L.P. bought $5.6M of Lexicon Pharmaceuticals, Inc.

Director and 10% owner

Bought$5,554,166
$9.64Price
575,946Shares
+1%Stake

What LXRX did for a copier

Prices for LXRX after this filing aren't in yet.

Invus Public Equities, L.P.'s record

5 other buys with 3 months of prices since 2017: on average −13.9% against the S&P 500, and 2 of 5 beat it.

We're building an app that can copy buys like this into your own brokerage. Join the waitlist

Traded Fri, Nov 10. Filed Tue, Nov 14, 2:32 PM ET, during the session. Not investment advice.